Table 4 Prevalence of primary and secondary study end-points for FVL G1691A, PT G20210A, and ACE-ins/del Genotypes.
From: Thrombotic gene polymorphisms and postoperative outcome after coronary artery bypass graft surgery
FVL 1691 G/G (n = 196) | FVL 1691 G/A (n = 24) | p value | PT 20210 G/G (n = 212) | PT 20210 G/A (n = 8) | p value | ACE I/I (n = 30) | ACE I/D (n = 94) | ACE D/D (n = 57) | p value | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
Re-exploration due to bleeding, n (%) | No | 193 (98.5) | 23 (95.8) | NS | 209 (98.6) | 7 (87.5) | NS | 29 (96.7) | 93 (98.9) | 55 (96.5) | NS |
Yes | 3 (1.5) | 1 (4.2) | 3 (1.4) | 1 (12.5) | 1 (3.3) | 1 (1.1) | 2 (3.5) | ||||
Perioperative acute MI, n (%) | No | 194 (99.0) | 24 (100) | NS | 211 (99.5) | 7 (87.5) | 0.072 | 29 (96.7) | 93 (98.9) | 55 (96.5) | NS |
Yes | 2 (1.0) | 0 | 1 (0.5) | 1 (12.5) | 1 (3.3) | 1 (1.1) | 2 (3.5) | ||||
Postoperative stroke, n (%) | No | 194 (99.0) | 24 (100) | NS | 210 (99.0) | 8 (100) | NS | 30 (100) | 93 (98.9) | 57 (100) | NS |
Yes | 2 (1.0) | 0 | 2 (0.9) | 0 | 0 | 1 (1.1) | 0 | ||||
Respiratory insufficiency, n (%) | No | 191 (97.5) | 24 (100) | NS | 207 (97.6) | 8 (100) | NS | 30 (100) | 92 (97.9) | 55 (96.5) | NS |
Yes | 5 (2.6) | 0 | 5 (2.4) | 0 | 0 | 2 (2.1) | 2 (3.5) | ||||
Renal insufficiency, n (%) | No | 191 (97.5) | 24 (100) | NS | 206 (97.2) | 8 (100) | NS | 30 (100) | 92 (97.9) | 55 (96.5) | NS |
Yes | 5 (2.6) | 0 | 5 (2.4) | 0 | 0 | 2 (2.1) | 2 (3.5) | ||||
Event-free survival, n (%) | No | 9 (4.6) | 1 (4.2) | NS | 9 (4.2) | 1 (12.5) | NS | 1 (3.3) | 4 (4.3) | 4 (7.0) | NS |
Yes | 187 (95.4) | 23 (95.8) | 203 (95.8) | 7 (87.5) | 29 (96.7) | 90 (95.7) | 53 (93.0) | ||||
Overall death at 5-years, n (%) | No | 189 (96.4) | 23 (95.8) | NS | 205 (96.7) | 7 (87.5) | NS | 30 (100) | 91 (96.8) | 54 (94.7) | NS |
Yes | 7 (3.6) | 1 (4.2) | 7 (3.3) | 1 (12.5) | 0 | 3 (3.2) | 3 (5.3) |